TRIAL DATA
Phase III trial shows survival benefit for tyrosine kinase inhibitor plus immunotherapy in pretreated microsatellite-stable colorectal cancer — ESMO Gastrointestinal Oncology
The interim analysis of the phase III STELLAR-303 trial demonstrated an overall survival benefit with the combination of zanzalintinib (a tyrosine kinase inhibitor, or TKI) plus atezolizumab (an immune checkpoint inhibitor) compared with regorafenib in pretreated microsatellite-stable colorectal cancer. Tyrosine kinase inhibitors can induce immunological reprogramming of the tumor microenvironment, promoting proinflammatory macrophage polarization, antigen presentation, vascular normalization, and T-cell infiltration, which may help overcome the intrinsic resistance of MSS tumors to immunotherapy.
What this means
This is the first phase III trial to show a survival advantage for combining a tyrosine kinase inhibitor with immunotherapy in microsatellite-stable colorectal cancer, a population that has historically not benefited from immunotherapy alone. The role of liver metastases in modulating response remains an area of active investigation.